|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...1819202122232425262728...6768» |
- ||| lenalidomide / Generic mfg.
New trial: A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=600, Recruiting, Sponsor: Celgene Corporation
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P2 trial, Combination therapy: ESBAM: Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis (clinicaltrials.gov) - Sep 22, 2015
P2, N=158, Recruiting, Sponsor: Assistance Publique - H
- Trial termination: Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Sep 21, 2015
P1/2, N=31, Terminated, Sponsor: University of Washington
Active, not recruiting --> Terminated; One of the study drugs is not available.
- ||| Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Enrollment closed: Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma (clinicaltrials.gov) - Sep 18, 2015
P1/2, N=55, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Terminated; One of the study drugs is not available. Recruiting --> Active, not recruiting
- | ontuxizumab (MORAb-004) / Eisai
Trial completion, Enrollment change: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Sep 18, 2015
P1, N=27, Completed, Sponsor: Morphotek
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=65 --> 27
- | Biostate (factor VIII/von Willebrand factor) / CSL Behring
New P4 trial: Study of Voncento® in Subjects With Von Willebrand Disease (clinicaltrials.gov) - Sep 17, 2015
P4, N=30, Not yet recruiting, Sponsor: CSL Behring
- |||||||||| Cablivi (caplacizumab) / Sanofi
New P3 trial: HERCULES: Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) - Sep 17, 2015
P3, N=92, Not yet recruiting, Sponsor: Ablynx
- ||| BeneFix (nonacog alfa) / Pfizer
Trial completion, Trial primary completion date: BeneFIX Drug Use Results Survey [All-Case Surveillance] (clinicaltrials.gov) - Sep 17, 2015
P=N/A, N=314, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed | N=65 --> 27 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> May 2014
- Alhemo (concizumab) / Novo Nordisk
Enrollment open: Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (clinicaltrials.gov) - Sep 16, 2015
P1, N=45, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> May 2014 Not yet recruiting --> Recruiting
- Clinical data, Enrollment closed: CoMMpass: Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (clinicaltrials.gov) - Sep 15, 2015
P=N/A, N=1000, Active, not recruiting, Sponsor: Multiple Myeloma Research Foundation
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Abstilla (lonoctocog alfa) / CSL Behring
Trial completion: Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A (clinicaltrials.gov) - Sep 14, 2015
P3, N=84, Completed, Sponsor: CSL Behring
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Darzalex (daratumumab) / J&J
Enrollment open, Combination therapy: A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 14, 2015
P1, N=6, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial primary completion date: Familial Myeloproliferative Disorders (clinicaltrials.gov) - Sep 11, 2015
P=N/A, N=200, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2012 --> Jun 2016
- Enrollment change, Trial primary completion date, Metastases: CRUKD/12/003: A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies (clinicaltrials.gov) - Sep 10, 2015
P1, N=28, Recruiting, Sponsor: Cancer Research UK
Trial primary completion date: Dec 2012 --> Jun 2016 N=40 --> 28 | Trial primary completion date: May 2018 --> Sep 2017
- |||| Zontivity (vorapaxar) / Merck (MSD)
Enrollment open, Trial initiation date: ADVICE: Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints (clinicaltrials.gov) - Sep 9, 2015
P1/2, N=60, Recruiting, Sponsor: Kirby Institute
N=40 --> 28 | Trial primary completion date: May 2018 --> Sep 2017 Not yet recruiting --> Recruiting | Initiation date: Jun 2015 --> Sep 2015
- || Sevenfact (eptacog beta activated) / LFB SA, HEMA Biologics
Trial completion: PERSEPT 1: Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors (clinicaltrials.gov) - Sep 8, 2015
P3, N=27, Completed, Sponsor: rEVO Biologics
Not yet recruiting --> Recruiting | Initiation date: Jun 2015 --> Sep 2015 Active, not recruiting --> Completed
- Coagadex (coagulation factor X (human)) / Bio Products Laboratory (BPL)
Enrollment change: A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years (clinicaltrials.gov) - Sep 5, 2015
P3, N=9, Recruiting, Sponsor: Bio Products Laboratory
Active, not recruiting --> Completed N=16 --> 9
- RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
New trial: TOP-CLOT: Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions (clinicaltrials.gov) - Sep 4, 2015
P=N/A, N=133, Not yet recruiting, Sponsor: Weill Medical College of Cornell University
- Biomarker, New trial: Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial (clinicaltrials.gov) - Sep 4, 2015
P=N/A, N=25, Enrolling by invitation, Sponsor: Novo Nordisk A/S
- Empliciti (elotuzumab) / AbbVie, BMS
New trial: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 4, 2015
P=N/A, N=0, No Longer Available, Sponsor: Sundar Jagannath
- New trial: Coagulation Disorders After Aneurysmatic Subarachnoid Haemorrhage (clinicaltrials.gov) - Sep 3, 2015
P=N/A, N=32, Not yet recruiting, Sponsor: Tampere University Hospital
- ||| New trial: Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients (clinicaltrials.gov) - Sep 3, 2015
P=N/A, N=164, Recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
- lenalidomide / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion, Trial primary completion date: A Dose Escalation Study of the Combination of Lenalidomide (Revlimid (clinicaltrials.gov) - Sep 3, 2015
P1/2, N=32, Completed, Sponsor: King's College Hospital NHS Trust
N=16 --> 9 Active, not recruiting --> Completed | Trial primary completion date: Apr 2010 --> Mar 2014
- ||| lenalidomide / Generic mfg.
Enrollment open, Enrollment change, Trial primary completion date: Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) (clinicaltrials.gov) - Sep 2, 2015
P=N/A, N=300, Recruiting, Sponsor: Celgene Corporation
Active, not recruiting --> Completed | Trial primary completion date: Apr 2010 --> Mar 2014 Not yet recruiting --> Recruiting | N=600 --> 300 | Trial primary completion date: Sep 2017 --> Nov 2016
- fludarabine IV / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker, Post-transplantation: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (clinicaltrials.gov) - Sep 1, 2015
P=N/A, N=5, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting | N=600 --> 300 | Trial primary completion date: Sep 2017 --> Nov 2016 Recruiting --> Completed | N=20 --> 5 | Trial primary completion date: Dec 2015 --> Nov 2014
- Eylea (aflibercept intravitreal) / Bayer, Regeneron
New P2 trial: EyNeP: Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE) (clinicaltrials.gov) - Sep 1, 2015
P2, N=20, Not yet recruiting, Sponsor: University Hospital, Bonn
- || lenalidomide / Generic mfg., sirolimus / Generic mfg.
Trial primary completion date: Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) (clinicaltrials.gov) - Aug 31, 2015
P1/2, N=53, Active, not recruiting, Sponsor: Indiana University School of Medicine
Recruiting --> Completed | N=20 --> 5 | Trial primary completion date: Dec 2015 --> Nov 2014 Trial primary completion date: Feb 2015 --> Dec 2015
- thalidomide / Generic mfg.
Enrollment closed, Trial primary completion date: THALI-HHT: Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia (clinicaltrials.gov) - Aug 31, 2015
P2, N=31, Active, not recruiting, Sponsor: IRCCS Policlinico S. Matteo
Trial primary completion date: Feb 2015 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Oct 2014
- || Ninlaro (ixazomib) / Takeda
Trial primary completion date: Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 28, 2015
P1, N=60, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Oct 2014 Trial primary completion date: Jan 2013 --> Sep 2012
- Xyntha (moroctocog alfa) / Pfizer
Enrollment open: Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A (clinicaltrials.gov) - Aug 28, 2015
P1, N=12, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jan 2013 --> Sep 2012 Not yet recruiting --> Recruiting
- ||| Enrollment open, Trial initiation date: Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation (clinicaltrials.gov) - Aug 27, 2015
P=N/A, N=300, Recruiting, Sponsor: Octapharma
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Aug 2015
- |||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders (clinicaltrials.gov) - Aug 27, 2015
P2, N=122, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Aug 2015 Active, not recruiting --> Completed
- bortezomib / Generic mfg., bendamustine / Generic mfg.
Trial primary completion date: Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma (clinicaltrials.gov) - Aug 25, 2015
P2, N=24, Active, not recruiting, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Feb 2014
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial termination: Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen (clinicaltrials.gov) - Aug 25, 2015
P2, N=22, Terminated, Sponsor: University of Michigan Cancer Center
Trial primary completion date: Dec 2015 --> Feb 2014 Active, not recruiting --> Terminated; Low accrual
- CB-5083 / Cleave Therap
Enrollment closed: A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (clinicaltrials.gov) - Aug 25, 2015
P1, N=50, Active, not recruiting, Sponsor: Cleave Biosciences, Inc.
Active, not recruiting --> Terminated; Low accrual Recruiting --> Active, not recruiting
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Enrollment closed, Trial primary completion date, Monotherapy: XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease (clinicaltrials.gov) - Aug 25, 2015
P1, N=22, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jun 2016
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) (clinicaltrials.gov) - Aug 25, 2015
P1, N=33, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jun 2016 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant (clinicaltrials.gov) - Aug 24, 2015
P2, N=10, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Jul 2017
- lenalidomide / Generic mfg.
Enrollment change: Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 24, 2015
P2, N=22, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Jul 2015 --> Jul 2017 N=40 --> 22
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer (clinicaltrials.gov) - Aug 24, 2015
P2, N=210, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=40 --> 22 Active, not recruiting --> Completed | N=100 --> 210 | Trial primary completion date: Dec 2015 --> Jan 2015
- Trial primary completion date, Heterogeneity: Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function (clinicaltrials.gov) - Aug 22, 2015
P=N/A, N=40, Recruiting, Sponsor: CancerCare Manitoba
Active, not recruiting --> Completed | N=100 --> 210 | Trial primary completion date: Dec 2015 --> Jan 2015 Trial primary completion date: Jun 2015 --> Oct 2015
- | melphalan / Generic mfg., amifostine / Generic mfg.
Trial completion: Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma (clinicaltrials.gov) - Aug 22, 2015
P3, N=130, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jun 2015 --> Oct 2015 Active, not recruiting --> Completed
- CB-5083 / Cleave Therap
Trial primary completion date: A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (clinicaltrials.gov) - Aug 21, 2015
P1, N=50, Recruiting, Sponsor: Cleave Biosciences, Inc.
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- bortezomib / Generic mfg., lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma (clinicaltrials.gov) - Aug 21, 2015
P1, N=12, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Aug 2015 --> Jan 2016
- |||| Farydak (panobinostat) / Secura Bio
Enrollment open, Combination therapy: Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients (clinicaltrials.gov) - Aug 21, 2015
P1/2, N=52, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Aug 2015 --> Jan 2016 Active, not recruiting --> Recruiting
- ||| Farydak (panobinostat) / Secura Bio
Enrollment closed, Combination therapy: Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients (clinicaltrials.gov) - Aug 20, 2015
P1/2, N=52, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | lenalidomide / Generic mfg.
Enrollment closed, Trial primary completion date: Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma (clinicaltrials.gov) - Aug 20, 2015
P3, N=194, Active, not recruiting, Sponsor: Gesellschaft fur Medizinische Innovation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Dec 2016
- |||| lenalidomide / Generic mfg.
Trial primary completion date: IFM2005-02: Maintenance Therapy Using Lenalidomide in Myeloma (clinicaltrials.gov) - Aug 20, 2015
P3, N=614, Active, not recruiting, Sponsor: University Hospital, Toulouse
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Dec 2016 Trial primary completion date: Feb 2015 --> Sep 2015
- Rituxan (rituximab) / Roche
Enrollment change: Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy (clinicaltrials.gov) - Aug 20, 2015
P2, N=0, Withdrawn, Sponsor: Hoag Memorial Hospital Presbyterian
Trial primary completion date: Feb 2015 --> Sep 2015 N=80 --> 0
- | fludarabine IV / Generic mfg.
Trial completion, Metastases: Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenstr (clinicaltrials.gov) - Aug 19, 2015
P3, N=414, Completed, Sponsor: French Study Group on Chronic Lymphoid Leukemia
N=80 --> 0 Recruiting --> Completed